Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 2Recurrence 1Hereditary Sensory and Autonomic Neuropathies 1

Interventions

duvelisib 3parsaclisib 1obinutuzumab 1liposomal doxorubicin 1chiauranib 1Taxes 1Rituximab 1Panobinostat 1Paclitaxel 1Lomustine 1Irinotecan 1Gemcitabine 1Everolimus 1Doxorubicin 1Carboplatin 1Albumin-Bound Paclitaxel 13-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hereditary Sensory and Autonomic Neuropathies × chiauranib × Lymphoid × Clear all
NCT03074825 2019-07-24

Study of Chiauranib in Relapsed/Refractory Non-Hodgkin's Lymphoma

Chipscreen Biosciences, Ltd.

Phase 1 Terminated
5 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Hereditary Sensory and Autonomic Neuropathies, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡